Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions
Hemophilia A
Interventions
DRUG

Emicizumab Injection

Emicizumab 0.8-1.5mg/kg weekly for 4 weeks as loading dose. Then 0.8-1.5mg/kg 4-weekly for 24 weeks will be used in Emicizumab group-I and Emicizumab Group- WI

DRUG

Factor VIII (FVIII)

10-15 unit/Kg thrice weekly (for conventional half-life products) or twice weekly (for extended half-life products) for 28 weeks. Inj. Factor VIII is available in 250U, 500U, 750U \& 1,000 IU vail sizes. Dose will be round up to full nearest full vail strength.

Trial Locations (1)

1000

Dhaka Medical College Hospital, Dhaka

Sponsors
All Listed Sponsors
lead

Dhaka Medical College

OTHER

NCT06938659 - Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients | Biotech Hunter | Biotech Hunter